In a report released today, John Hester from Bell Potter maintained a Buy rating on Mesoblast Limited, with a price target of A$4.00. The company’s shares closed today at $1.90.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hester covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Mesoblast Limited, and Sigma Healthcare Ltd. According to TipRanks, Hester has an average return of 17.1% and a 56.88% success rate on recommended stocks.
Mesoblast Limited has an analyst consensus of Moderate Buy, with a price target consensus of $2.03, representing a 6.84% upside. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a A$3.11 price target.
The company has a one-year high of $5.34 and a one-year low of $0.70. Currently, Mesoblast Limited has an average volume of 760.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MEOBF in relation to earlier this year.
Read More on MEOBF:
Disclaimer & DisclosureReport an Issue
- Mesoblast Reports 66% Revenue Surge for Ryoncil in Second Quarter
- Mesoblast reports Q2 Ryoncil revenue up 66% y/y
- Mesoblast receives J-Code for Ryoncil from Medicare & Medicaid Services
- Mesoblast’s Ryoncil® Gains Medicare & Medicaid J-Code for Enhanced Access
- Mesoblast’s U.S. Origin Cell Therapies Exempt from Tariffs
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Data%20Center%20by%20Caureem%20via%20Shutterstock%20(2).jpg)
/Nvidia%20logo%20on%20phone%20screen%20with%20stock%20chart%20by%20xalien%20via%20Shutterstock.jpg)